Table 3

Changes in bone marrow lesion scores (BML) versus baseline

CS (800 mg/day)Placebo
RegionMonthMeanSDMeanSDp Value
Global60.131.390.201.060.461
12−0.571.830.431.700.062
Lateral compartment60.030.400.130.430.153
12−0.130.510.431.270.035
Medial compartment60.091.280.071.011.000
12−0.431.740.001.000.287
Condyles60.090.780.070.780.879
12−0.431.140.261.140.075
Lateral condyle6−0.030.180.070.250.085
12−0.070.370.350.980.044
Medial condyle60.130.750.000.740.432
12−0.371.00−0.090.730.450
Tibial plateaus60.030.820.130.680.374
12−0.130.940.170.980.347
Lateral tibial plateau60.060.350.070.370.644
12−0.070.250.090.670.358
Medial tibial plateau6−0.030.740.070.520.303
12−0.070.910.090.730.732
Trochlea60.160.630.000.450.379
12−0.070.940.130.630.222
  • p Values were assessed by two-sided Mann–Whitney U test.

  • n=32/30 for CS, n=29/23 for placebo at 6 and 12 months, respectively.

  • CS, chondroitin sulphate.